| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (NCT04892875) | Jennifer Choe | 2023-12-31 |
| Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis (NCT06137651) | Northwestern University | 2023-12-31 |
| Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases (NCT05903937) | Vastra Gotaland Region | 2023-12-31 |
| A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors (NCT04947033) | I-Mab Biopharma US Limited | 2023-12-31 |
| Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults (NCT04620291) | United BioPharma | 2023-12-31 |
| Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma (NCT06180174) | Chongqing Precision Biotech Co., Ltd | 2023-12-31 |
| Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis (NCT05986162) | Biotech Pharmaceutical Co., Ltd. | 2023-12-30 |
| First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study (NCT06130722) | Suzhou Forlong Biotechnology Co., Ltd | 2023-12-30 |
| Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism (NCT06773663) | Peking Union Medical College Hospital | 2023-12-30 |
| Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria (NCT04175704) | United BioPharma | 2023-12-30 |
| A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer (NCT06110793) | Memorial Sloan Kettering Cancer Center | 2023-12-29 |
| A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas (NCT06090539) | Bristol-Myers Squibb | 2023-12-29 |
| AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia (NCT06137118) | AstraZeneca | 2023-12-29 |
| Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas (NCT06225921) | West China Hospital | 2023-12-29 |
| Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function (NCT06145282) | National Heart, Lung, and Blood Institute (NHLBI) | 2023-12-28 |
| Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants (NCT06279741) | EXO Biologics S.A. | 2023-12-28 |
| Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors (NCT06234397) | Hanmi Pharmaceutical Company Limited | 2023-12-28 |
| A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation (NCT06039384) | Incyte Corporation | 2023-12-28 |
| A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC) (NCT06197178) | Peking University | 2023-12-28 |
| A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer (NCT06172322) | Nanjing Chia-tai Tianqing Pharmaceutical | 2023-12-28 |
| Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy (NCT05905328) | CytoAgents, Inc. | 2023-12-28 |
| A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants (NCT06178783) | Insmed Incorporated | 2023-12-27 |
| Relative Bioavailability Study of HR19042 in Healthy Subjects (NCT06922305) | Jiangsu HengRui Medicine Co., Ltd. | 2023-12-27 |
| Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC (NCT06173505) | Xencor, Inc. | 2023-12-27 |
| Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination (NCT06167915) | Guangzhou Patronus Biotech Co., Ltd. | 2023-12-26 |
| A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma (NCT06235229) | Gracell Biotechnologies (Shanghai) Co., Ltd. | 2023-12-26 |
| A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects (NCT06160895) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-12-26 |
| SG2918 For Advanced Malignant Tumors (NCT06167486) | Hangzhou Sumgen Biotech Co., Ltd. | 2023-12-26 |
| A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients (NCT06155084) | Hinova Pharmaceuticals Inc. | 2023-12-26 |
| A Single-Arm Phase Ic Clinical Study of XKH001 Injection in Patients With Allergic Asthma After Multiple Doses (NCT07070297) | Zhejiang Kanova Biopharmaceutical Co., LTD | 2023-12-26 |
| A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma (NCT06205407) | Pfizer | 2023-12-26 |
| The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM (NCT06616727) | Shanghai Simnova Biotechnology Co.,Ltd. | 2023-12-26 |
| Assessment of Gastric Emptying by SHR20004 in Healthy Subjects (NCT06137469) | Jiangsu HengRui Medicine Co., Ltd. | 2023-12-26 |
| A Phase I Study of XH-S002 in Healthy Volunteers (NCT06204419) | S-INFINITY Pharmaceuticals Co., Ltd | 2023-12-26 |
| The Mass Balance Study of LP-168 in Healthy Subjects (NCT06126861) | Guangzhou Lupeng Pharmaceutical Company LTD. | 2023-12-25 |
| Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis (NCT07439848) | PT. Prodia Stem Cell Indonesia | 2023-12-25 |
| The Efficacy and Safety of IBI363 in Solid Tumors (NCT06081907) | Hunan Province Tumor Hospital | 2023-12-25 |
| A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects (NCT06350279) | Haisco Pharmaceutical Group Co., Ltd. | 2023-12-25 |
| Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer (NCT06776757) | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | 2023-12-25 |
| Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) (NCT06196255) | Xuzhou Medical University | 2023-12-25 |
| An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors (NCT06094556) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2023-12-25 |
| A Study in Healthy Men to Test How Well Different Doses of BI 1584862 Are Tolerated (NCT06148948) | Boehringer Ingelheim | 2023-12-25 |
| Safety and Pharmacokinetics/ Pharmacodynamics of Methoxyethyl Etomidate Hydrochloride in Healthy Elderly Subjects (NCT06764147) | Ahon Pharmaceutical Co., Ltd. | 2023-12-25 |
| DBM-1152A Inhalation Solution in Chinese Healthy Subjects (NCT07447141) | Joincare Pharmaceutical Group Industry Co., Ltd | 2023-12-24 |
| A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices (NCT06182384) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2023-12-24 |
| C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma (NCT06210243) | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 2023-12-24 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B" (NCT06184269) | Boryung Pharmaceutical Co., Ltd | 2023-12-23 |
| A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies (NCT06181032) | First Affiliated Hospital of Fujian Medical University | 2023-12-23 |
| Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine (NCT06184542) | Institute of Medical Biology, Chinese Academy of Medical Sciences | 2023-12-23 |
| Safety, Pharmacokinetics, and Food Effect of PS1 in Subjects (NCT05176210) | Pharmasaga Co. Ltd. | 2023-12-22 |
| Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration (NCT06132035) | Caregen Co. Ltd. | 2023-12-22 |
| Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis (NCT06162507) | Keymed Biosciences Co.Ltd | 2023-12-22 |
| A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma (NCT06173999) | Jiangsu HengRui Medicine Co., Ltd. | 2023-12-22 |
| Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer (NCT06139575) | Bivision Pharmaceuticals, Inc. | 2023-12-22 |
| Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes (NCT05490381) | University of Washington | 2023-12-21 |
| A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood (NCT05896384) | Boehringer Ingelheim | 2023-12-21 |
| Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies (NCT05981209) | Abdullah Khan | 2023-12-21 |
| Pharmacokinetic and Safety Studies of HRS-7535 in Subjects With Moderate Renal Insufficiency and Healthy Subjects (NCT06132204) | Shandong Suncadia Medicine Co., Ltd. | 2023-12-21 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years (NCT06225115) | Kynexis B.V. | 2023-12-21 |
| Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in the Postprandial State in Healthy Chinese Subjects (NCT06180720) | The Affiliated Hospital of Qingdao University | 2023-12-20 |
| Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma (NCT07529613) | National Cancer Center Hospital East | 2023-12-20 |
| A Study of LM-24C5 For Advanced Solid Tumors (NCT06187402) | LaNova Medicines Limited | 2023-12-20 |
| Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants (NCT06157918) | Shanghai Runshi Pharmaceutical Technology Co., Ltd | 2023-12-20 |
| A Study to Test How Different Doses of Nerandomilast (BI 1015550) Are Taken up in the Body of Healthy Japanese Men (NCT06139302) | Boehringer Ingelheim | 2023-12-20 |
| A Study of TAVO412 in Patients with Cancer (TAVO412) (NCT06761651) | Tavotek Biotherapeutics | 2023-12-20 |
| A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants (NCT06177457) | Pfizer | 2023-12-20 |
| A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over (NCT06123663) | CanSino Biologics Inc. | 2023-12-20 |
| First in Human Study Evaluating Single Ascending Oral Doses of YCT-529 in Healthy Males (NCT06094283) | YourChoice Therapeutics, Inc. | 2023-12-20 |
| A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants (NCT06140290) | Pfizer | 2023-12-20 |
| A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults (NCT06132867) | Takeda | 2023-12-20 |
| Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer (NCT06167694) | Shandong Suncadia Medicine Co., Ltd. | 2023-12-20 |
| Safety and Efficacy Evaluation of Next-generation CD19-UCART (NCT05381181) | Bioray Laboratories | 2023-12-20 |
| A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418 (NCT05995782) | 1ST Biotherapeutics, Inc. | 2023-12-20 |
| Pharmacokinetic Study of Single and Multiple Intravenous Administration of Nalbuphine Hydrochloride Injection in Healthy Chinese Volunteers (NCT06902103) | Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd | 2023-12-20 |
| A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults (NCT06182124) | Pfizer | 2023-12-20 |
| Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma (NCT06118086) | Remix Therapeutics | 2023-12-20 |
| A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms (NCT06150157) | Janssen Research & Development, LLC | 2023-12-20 |
| A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262 (NCT06145607) | Calico Life Sciences LLC | 2023-12-19 |
| Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) (NCT05859776) | AsclepiX Therapeutics, Inc. | 2023-12-19 |
| Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects (NCT06216054) | Luye Pharma Group Ltd. | 2023-12-19 |
| Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency (NCT06090669) | National Cancer Institute (NCI) | 2023-12-19 |
| A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment (NCT05828511) | Regeneron Pharmaceuticals | 2023-12-19 |
| Lopinavir/Ritonavir in PLWH With High-Grade AIN (NCT05334004) | University of Wisconsin, Madison | 2023-12-19 |
| Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma (NCT06016920) | Nykode Therapeutics ASA | 2023-12-19 |
| oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection (NCT05938296) | Binhui Biopharmaceutical Co., Ltd. | 2023-12-19 |
| A Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of THDBH120 Injection in Healthy Subjects (NCT06744868) | Tonghua Dongbao Pharmaceutical Co.,Ltd | 2023-12-19 |
| Preoperative Radiotherapy And ASTX660 in Rectum Cancer (NCT05912075) | Gustave Roussy, Cancer Campus, Grand Paris | 2023-12-19 |
| Study of IK-595 in RAS- or RAF-altered Advanced Tumors (NCT06270082) | Ikena Oncology | 2023-12-18 |
| A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants (NCT06168318) | ViiV Healthcare | 2023-12-18 |
| Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study (NCT06162559) | The Netherlands Cancer Institute | 2023-12-18 |
| A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus (NCT05835986) | Hoffmann-La Roche | 2023-12-18 |
| Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms (NCT06034470) | Fred Hutchinson Cancer Center | 2023-12-18 |
| Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer (NCT06005324) | University of Chicago | 2023-12-18 |
| A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children. (NCT06188026) | Novo Nordisk A/S | 2023-12-18 |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (NCT05950464) | National Cancer Institute (NCI) | 2023-12-18 |
| A Study of HY-0102 in Patients With Advanced Solid Tumors (NCT06094777) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2023-12-18 |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma (NCT04234048) | SciTech Development, Inc. | 2023-12-18 |
| [18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma (NCT05390814) | Assistance Publique - Hôpitaux de Paris | 2023-12-18 |
| Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia (NCT05971251) | University of Alabama at Birmingham | 2023-12-18 |
| Doxil/Caelyx BE Study (NCT05567601) | Baxter Healthcare Corporation | 2023-12-16 |